Overview

ZS Ph2/3 Dose-response Study in Japan

Status:
Completed

Trial end date:
2018-02-23

Target enrollment:

Participant gender:

Summary

To assess efficacy of 5 g three times daily (TID) and 10 g TID ZS versus placebo in Japanese patients with hyperkalemia (serum potassium [S-K] ≥ 5.1 mmol/L and ≤ 6.5 mmol/L).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

AstraZeneca